About Synnovation Therapeutics
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, with a focus on oncology. Founded by an experienced medicinal chemistry team, the company builds a pipeline of novel targeted cancer therapies — including its lead PARP1 inhibitor SNV1521 and PI3Kα inhibitor SNV4818 — aimed at improving outcomes for patients with significant unmet medical needs. Its customers are cancer patients and clinical trial participants, served through partnerships with major pharmaceutical companies and academic medical centers.
Company details
Funding
Total raised
$139M
Last stage
Series A
Investors
Founders
Wenqing Yao
Former head of discovery chemistry at Incyte for ~19 years, where he contributed to 5 approved drugs. Co-founded Synnovation Therapeutics in 2021.
LinkedInLiangxing Wu
Incyte veteran who co-founded Synnovation Therapeutics alongside Wenqing Yao in 2021.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.